Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG vs Citrafleet in IBD
NCT07786363Completed
- Sponsor
- Medical University of Warsaw
- Start
- Jun 2023
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Randomised, open-label trial of polyethylene glycol 3350 + bisacodyl, sodium picosulfate and magnesium oxide in inflammatory bowel disease (IBD) (2 arms), sponsored by Medical University of Warsaw. Primary endpoint: Bowel preparation of the whole colon. Started Jun 2023; status: completed.
02
Drugs
polyethylene glycol 3350 + bisacodylsodium picosulfatemagnesium oxide
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07786363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07786363.